As a development of the “Make in India” campaign, the Central government of India is planning for a slew of policies to push the growth of medical technology sector. Evolution in regulation of the medical products, separate legislation, overhauling tax structure for domestic manufacturing said Dr VK Subburaj, secretary, department of pharmaceuticals (DoP) in a medical conference held at New Delhi. The theme of the conference was “Achieving $50 billion turnover by 2025”. READ ALSO: Achievements of the CDSCO (Regulatory Body of India) 2014.
The growth of Healthcare Sector in India will be 4 to 5 times higher than current growth if separate regulatory body regulates the industry” he added. The office of the Prime Minister is showing keen interest in developing medical equipment domestic production and the DoP to implement schemes without any delay. Above two –thirds of the medical equipments are imported in India and few of the Indian manufactured are competitive in both price and quality. In India, there are around 800 units. The number units would increase in the near future. Dr Subburaj also insisted on the important aspect of accessibility and affordability for the people. Currently only 1.5 to 2 lakh surgeries per year are performed in India whereas the demand is around 25 lakhs. This shows the cost effective medical systems would have a great scope of increasing the healthcare market in India. READ ALSO: Manufacturing License in India – document requirements.
Other News
India Medical Device Pricing Strategy: Ensuring Growth & Affordability
India’s National Pharmaceutical Pricing Authority (NPPA) is developing a specialized India medical device pricing strategy for medical devices, transitioning away from the conventional drug-centric framework. This innovative strategy will incorporate international pricing tactics tailored to […]
Read MoreImports of High-Value Medical Equipment
High-Value Medical Equipment The Central Drugs Standard Control Organization (CDSCO) and the Central Board of Indirect Taxes & Customs have released a new circular, “F.No.401/40/2021-Cus.III,” detailing updated policies on the import of used high-end medical […]
Read MoreSEC Committee: Pioneering Medical Approvals
New important article released by Central Drugs Standard Control Organization (CDSCO) titled “SEC – Special Expert Committee, Medical Devices”. Key highlights include the streamlined processes for CDSCO application evaluations, preparation and significance of briefing materials, […]
Read MoreErlySign Oral Cancer Detection Technology Gets CDSCO Nod
ErlySign, a Nagpur-based biotech startup, has received approval from the Central Drugs Standard Control Organization (CDSCO) to conduct large-scale clinical trials for its novel oral cancer detection technology. The approval for ErlySign follows a rigorous […]
Read MoreAdditional Steps Announced by FDA to Modernize Clinical Trials
The U.S. Food and Drug Administration has made draft guidance available with updated recommendations for good clinical practices (GCPs), which are intended to modernize the clinical trial design and conduct while maintaining data integrity and […]
Read MoreAccreditation and Registration Numbers for Foreign Manufacturers Publication by PMDA
This article deals In accordance with the Pharmaceuticals and Medical Devices Act (PMD Act) of Japan, foreign businesses that wish to produce pharmaceuticals, quackery products, active pharmaceutical ingredients (APIs), or medical devices abroad and import […]
Read MoreBSI New Certification to Mitigate Antimicrobial Resistance Risk in Antibiotic Manufacturing
BSI, the business improvement and standards company, has developed a new certification to mitigate the risk of antimicrobial resistance (AMR) in antibiotic manufacturing. The certification, called the Minimized Risk of Antimicrobial Resistance (AMR) certification, will […]
Read MoreTUV SUD Inspects IVD Medical Devices’ Cyber Security
The growing digital connectivity of medical infrastructure is resulting in complicated systems with a plethora of diverse interfaces that are potentially vulnerable to assault. The IVD requires producers to provide proof of cyber security before […]
Read More